Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea to Prevent Cardiovascular Disease

PHASE3UnknownINTERVENTIONAL
Enrollment

2,500

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Sleep ApneaCardiovascular Disease
Interventions
DEVICE

Continuous Positive Airway Pressure (CPAP)

CPAP worn nightly

OTHER

Standard care

Standard care of cardiovascular risk factors

Trial Locations (5)

5041

Adelaide Institute for Sleep Health, Repatriation General Hospital, Adelaide

100088

Regional Coordinating Centre China: The George Institute China Beijing, Beijing

Unknown

Brazil Principal Investigator: Geraldo Lorenzi Filho, Heart Institute, University of São Paulo, São Paulo

500 033

Regional Coordinating Centre India: The George Institute India 839C, Road No. 44A Jubilee Hills, Hyderabad

08029

Regional Coordinating Centre Spain: Spanish Respiratory Society (Sociedad Española de Neumología y Cirugía Torácica) (SEPAR), Barcelona

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Philips Respironics

INDUSTRY

collaborator

National Health and Medical Research Council, Australia

OTHER

collaborator

ResMed

INDUSTRY

collaborator

Fisher and Paykel Healthcare

INDUSTRY

collaborator

The George Institute

OTHER

collaborator

Health Research Council, New Zealand

OTHER

lead

Adelaide Institute for Sleep Health

OTHER

NCT00738179 - Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea to Prevent Cardiovascular Disease | Biotech Hunter | Biotech Hunter